Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EDIT vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 48.4 HOLD), While EDIT Leads 5–1 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: EDIT 5 – 1 DMAC Matrix Metrics: EDIT 2 – 6 DMAC

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (46.3/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (6–2 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
  • Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EDIT vs DMAC
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
TTM Revenue $50M
Forward P/E N/M
Beta / 30D Vol 2.32β · 102% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.3%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.52 · SMA50: $2.61
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (EDIT 5 – 1 DMAC)

Columns: Metric · EDIT · DMAC
1. Valuation Multiples EDIT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 5.2x N/M
2. Growth & Scale EDIT
Revenue Growth (YoY) +37.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $50M N/A
Market Cap $336.5M $503.1M
3. Profitability & Quality DMAC
Gross Margin -73.3% N/A
Operating Margin -167.0% 0.0%
Net Profit Margin -144.9% 0.0%
Return on Equity (ROE) -147.4% -114.6%
4. Balance Sheet & Cash Flow EDIT
Cash Generation (TTM) -$110M -$32M
Cash Flow Margin N/A N/A
Net Cash / Leverage $79M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EDIT
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 95.8% (38th %ile) 106.3% (14th %ile)
Put/Call OI Skew 0.29x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat EDIT
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EDIT (2) vs DMAC (6)
Institutional Metric EDIT DMAC Criterion Row Edge
Market Capitalization
Scale
$336.5M $503.1M Larger Scale DMAC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+37.4% +0.0% Higher Growth EDIT
Operating Margin (TTM)
Profitability
-167.0% 0.0% Higher Margin DMAC
Net Profit Margin
Profitability
-144.9% 0.0% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-147.4% -114.6% Higher ROE DMAC
52-Week Range Position
Momentum
11% ($2–$4) 55% ($5–$11) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
2.32β · 102% Vol 1.74β · 98% Vol Lower Realized Risk DMAC
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite EDIT
Trailing 12M Revenue (USD)
Operating Scale
$50M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-73.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($79M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +30.1 pp
EDIT: -18.94% · DMAC: +11.16%
3M Horizon DMAC +61.16 pp
EDIT: -33.85% · DMAC: +27.31%
6M Horizon DMAC +72.85 pp
EDIT: -24.7% · DMAC: +48.15%
1Y Horizon DMAC +80.26 pp
EDIT: -25.0% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EDIT Revenue DMAC Revenue EDIT Op. Margin DMAC Op. Margin Margin Leader
FY2018 $30M $0M -356.1% -1352.2% EDIT
FY2019 $20M N/A -686.4% N/A EDIT
FY2020 $90M N/A -148.6% N/A EDIT
FY2021 $30M N/A -756.1% N/A EDIT
FY2022 $20M N/A -1146.3% N/A EDIT
FY2023 $80M N/A -216.6% N/A EDIT
FY2024 $30M N/A -777.2% N/A EDIT
FY2025 $40M N/A -394.9% N/A EDIT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EDIT BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 95.8%
IV Percentile 38th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EDIT Moat Profile Concentrated Oligopoly Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $336.5M market capitalization and -167.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EDIT vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (46.3/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. EDIT trades at $1.91 (N/M Forward P/E, -167.0% operating margin) versus DMAC at $8.41 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (6–2 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: EDIT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EDIT leads the Growth & Scale pillar: EDIT posts +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EDIT cumulative revenue shifted +33.3% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, EDIT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

EDIT screens cheaper on headline valuation multiples. EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDIT (-147.4% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.